Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2

Journal of Neurology

Volumn 261, Issue 5, 2014, Pages 963-969

  Ferner, Rosalie E ^a,b,c   Shaw, Adam ^a,d   Evans, D Gareth ^a,e   McAleer, Dympna ^a,e   Halliday, Dorothy ^a,f   Parry, Allyson ^a,f   Raymond, F Lucy ^a,g   Durie Gair, Juliette ^a,h   Hanemann, C Oliver ^a,i   Hornigold, Rachel ^a,b   Axon, Patrick ^a,h   Golding, John F ^a,j  

^a National Neurofibromatosis 2 Service   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^f OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h ADDENBROOKE S HOSPITAL   (United Kingdom)

ⁱ PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^j UNIVERSITY OF WESTMINSTER   (United Kingdom)

more..

Author keywords

Neurofibromatosis 2; NF2; NFTI QOL; Vestibular schwannoma

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CORRELATION ANALYSIS; CRONBACH ALPHA COEFFICIENT; DISEASE SEVERITY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; INTERNAL RELIABILITY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEUROFIBROMATOSIS; NEUROFIBROMATOSIS 2 IMPACT ON QUALITY OF LIFE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RELIABILITY; SCORING SYSTEM; SYMPTOMATOLOGY; TEST RETEST RELIABILITY; CLINICAL TRIAL; COHORT ANALYSIS; EVALUATION STUDY; MIDDLE AGED; MULTICENTER STUDY; NEUROFIBROMATOSIS 2; PSYCHOLOGY; STANDARDS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROFIBROMATOSIS 2; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84901938898     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7303-1     Document Type: Article

References (19)

1. Evans DG (2009) Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 4:16
2. Evans DGR, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F (2010) Birth incidence and prevalence of tumour prone syndromes: estimates from a UK genetic family register service. Am J Med Genet A 152A(2):327-332
3. Ferner R (2007) Neurofibromatosis 1 and neurofibromatosis 2: a twenty-first century perspective. Lancet Neurol 6(4):340-345
4. Patel CM, Ferner R, Grunfeld EA (2011) A qualitative study of the impact of living with neurofibromatosis type 2. Psychol Health Med 16(1):19-28
5. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B, Pulst SM, Lenoir G, Bijlsma E, Fashold R, Dumanski J, De Jong P, Parry D, Eldridge R, Aurias A, Delattre O, Thomas G (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363(6429):515-521 (Pubitemid 23186636)
6. Ruttledge MH, Andermann AA, Phelan CM, Claudio JO, Han FY, Chretien N, Rangaratnam S, MacCollin M, Short P, Parry D, Michels V, Riccardi VM, Weksberg R, Kitamura K, Bradburn JM, Hall BD, Propping P, Rouleau GA (1996) Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 59(2):331-427
7. Evans DGR, Trueman L, Wallace A, Collins S, Strachan T (1998) Genotype/phenotype correlations in type 2 neurofibromatosis: evidence for more severe disease with truncating mutations. J Med Genet 35(6):450-455 (Pubitemid 28252151)
8. Blakeley JO, Evans DG, Adler J, Brackmann D, Chen R, Ferner RE, Hanemann CO, Harris G, Huson SM, Jacob A, Kalamarides M, Karajannis MA, Korf BR, Mautner VF, McClatchey AI, Miao H, Plotkin SR, Slattery W 3rd, Stemmer-Rachamimov AO, Welling DB, Wen PY, Widemann B, Hunter-Schaedle K, Giovannini M (2012) Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A 158A(1):24-41
9. Plotkin SR, Stemmer-Rachamimov AO, Barker FG, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Eng J Med 361(14):358-367
10. Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG 2nd (2012) Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 33(6):1046-1052
11. Karajannis MA, Legault G, Hagiwara M, Ballas MS, Brown K, Nusbaum AO, Hochman T, Goldberg JD, Koch KM, Golfinos JG, Roland JT, Allen JC (2012) Phase II trial of lapatinib in adult and paediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neurol Oncol 14(9):1163-1170
12. Neary WJ, Hillier VF, Flute T, Stephens SD, Ramsden RT, Evans DG (2010) The relationship between patients' perception of the effects of neurofibromatosis type 2 and the domains of the short form-36. Clin Otolaryngol 35(4):291-299
13. Ware JE, Snow KK, Kosinski M, Gandek B (1993) SF-36 health survey. Manual and interpretation guide. The Health Institute, Boston
14. Hornigold RE, Golding JF, Leschziner G, Obholzer R, Gleeson MJ, Thomas N, Walsh D, Saeed S, Ferner RE (2012) The NFTI-QOL: a disease specific quality of life questionnaire for neurofibromatosis 2. J Neurol Surg Part B Skull Base 273(2):104-111
15. Baser ME, Kuramoto L, Woods R, Joe H, Friedman JM, Wallace AJ, Ramsden RT, Olschwang S, Bijlsma E, Kalamarides M, Papi L, Kato R, Carroll J, Lázaro C, Joncourt F, Parry DM, Rouleau GA, Evans DG (2005) The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2. J Med Genet 42:540-546 (Pubitemid 40993828)
16. The Euroqol Group (1990) Euroqol-a new facility for the measurement of health-related quality of life. Health Policy 16:199-208
17. Selvanathan SK, Shenton A, Ferner R, Wallace AJ, Huson SM, Ramsden RT, Evans DG (2010) Further genotype-phenotype correlations in neurofibromatosis type 2. Clin Genet 77(2):163-170
18. Smith MJ, Higgs JE, Bowers NL, Halliday D, Paterson J, Gillespie J, Huson SM, Freeman SR, Lloyd S, Rutherford SA, King AT, Wallace AJ, Ramsden RT, Evans DG (2011) Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset. J Med Genet 48(4):261-265
19. Evans D, Bowers N, Huson S, Wallace A (2013) Mutation type and position varies between mosaic and inherited NF2 and correlates with disease severity. Clin Genet 83:594-595